Express Pharma
Home  »  Deals  »  Healthcare industry reported 70 deals worth $6.2 billion in January 2021: GlobalData

Healthcare industry reported 70 deals worth $6.2 billion in January 2021: GlobalData

Deal value decreased by 89 per cent in Jan 2021, compared to Dec 2020

0 314
Read Article

In January 2021, the healthcare industry reported 70 deals worth $6.2 billion as compared to last 12-month average (January 2020 to December 2020) of 87 deals worth $17.1 billion.

Sanofi, a pharma company to acquire Kymab, a clinical-stage biopharma company focusing on developing fully human monoclonal antibody therapeutics for approximately $1.4 billion; Angelini Pharma, a pharma company to acquire Arvelle Therapeutics, a biopharma company for $960 million; Thermo Fisher Scientific, to acquire Henogen S.A., a biotech company for $880.8 million and Nordic Capital, to acquire Advanz Pharma Corp, a pharma company for $846 million were some of the major deals that contributed 66 per cent of the total deal value during January 2021.

Deal Date

Acquirer (s)

Target

Deal Value ($ m)

11-Jan-21

Sanofi (France)

Kymab Ltd (UK)

1,450.0

4-Jan-21

Angelini Spa (Italy)

Arvelle Therapeutics GmbH (Switzerland)

960.0

15-Jan-21

Thermo Fisher Scientific Inc (US)

Henogen S.A. (Belgium)

880.8

27-Jan-21

Nordic Capital Ltd (Sweden)

Advanz Pharma Corp Ltd (UK)

846.0

8-Jan-21

Chimerix Inc (US)

Oncoceutics Inc (US)

438.0

VC investments decreased by three per cent in January 2021, compared to December 2020

The healthcare industry reported 77 venture capital (VC) deals worth $4.4 billion in January 2021, compared to last 12-month average (January 2020 to December 2020) of 124 deals worth $3.2 billion.

EQRx, a biotechnology company raising $500 million in series B financing round for the development of late-stage cancer therapies, pipeline expansion and business growth; Affinivax, a clinical stage biopharma company raising $226 million in series C round of financing to advance its pipeline of Novel MAPS vaccines targeting infectious diseases and New Amsterdam Pharma, a clinical stage company raising $196 million in series A round of financing to support the Phase 3 development of its ApoB and LDL-c lowering small molecule drug—obicetrapib—are the major VC deals reported in January 2021.

Deal Date

Acquirer (s)

Target

Deal Value ($ m)

11-Jan-21

Nextech Invest Ltd; Arboretum Ventures LLC; ARCH Venture Partners LP; Andreessen Horowitz LLC; Casdin Capital LLC; Section 32; GV Management Co LLC; Undisclosed Investor

EQRx Inc (US)

500.0

8-Jan-21

BlackRock Inc; Viking Global Investors LP; Wellington Management Company LLP; EcoR1 Capital LLC; HealthCare Ventures LLC; Foresite Capital Management LLC; Perceptive Advisors LLC; Cormorant Asset Management LLC; Rock Springs Capital Management LP; Bain Capital Life Sciences; T Rowe Price Associates Inc; Surveyor Capital Ltd; Logos Global Management LLC

Affinivax Inc (US)

226.0

14-Jan-21

Medpace Inc; Forbion Capital Partners Management Services BV; Morningside Ventures; Peter Thiel; JVC Investment Partners LLC; GL Capital Group; BVF Partners LP; Kaiser Foundation Hospitals (Inactive); Janus Henderson Investors; Presight Capital; Population Health Partners LLC; Ascendant BioCapital; LSP Dementia Fund

New Amsterdam Pharma BV (Netherlands)

196.0

7-Jan-21

Wellington Management Company LLP; Omega Fund Management LLC; Orbimed Advisors LLC; Undisclosed Investor(s); Nextech Invest Ltd; EcoR1 Capital LLC; Atlas Venture Inc; Abingworth LLP; Boxer Capital LLC; Casdin Capital LLC; Invus LP; Janus Henderson Investors; Vida Ventures LLC; Surveyor Capital Ltd; Logos Global Management LLC; Woodline Partners

Scorpion Therapeutics Inc. (US)

162.0

13-Jan-21

Kurma Partners SA; RA Capital Management, LP; Novo Seeds; Sunstone Capital A/S; HBM Healthcare Investments Ltd; IDInvest Partners; Samsara BioCapital LLC; Vivo Capital LLC; Soleus Capital Management LP; Avoro Capital Advisors LLC; EIR Ventures; Serrado Capital LLC; PFM Health Sciences LP; Lundbeckfonden Emerge

IO Biotech ApS (Denmark)

154.5

 

 

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image